IMMUNOGENETICS OF HYBRID RESISTANCE

混合抗性的免疫遗传学

基本信息

  • 批准号:
    3174577
  • 负责人:
  • 金额:
    $ 8.79万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1984
  • 资助国家:
    美国
  • 起止时间:
    1984-03-01 至 1990-02-28
  • 项目状态:
    已结题

项目摘要

The long-term goal is to determine the genetic mechanism of expression of Hemopoietic histocompatibility (Hh) antigens on the surface of leukemic and normal progenitor cells and characterize the Hh molecules themselves. To that end the following Aims are described: 1. Confirm the conclusion that Hh antigenic expression on lymphoma cells is "down-regulated" by trans-acting regulatory genes. Using both in vivo and in vitro assays for hybrid resistance in which "cold target cells competition" can be measured, we observed that ACCb H-2d/H-2b loss mutants which had lost Dd gained the expression of Hhb. 2. Map the Hh genes more precisely. B10.RQDB is a new H-2 recombinant described by Chella David, which expresses Dd, Db, but not Ld. Therefore, recombination occurred between D and L and Db is really Lb. The marrow cells have lost Hhb, retained Hhd for allogenic hosts and have decreased Hhd for F1 hybrid hosts. There and other new recombinants will be used to map Hh, which should be contromeric to L since the sequence is D (R) L in the D-region. (3) Test the cis gene hypothesis, i.e. an adjacent gene regulates Hh expression. Use same new H-2 recombination to detect gene(s) between S and L which may regulate Hh expression in heterozygotes that regulated "tolerance" to parental Hh antigen. (4) Continue to test the "allogenic inhibition" hypothesis for hybrid resistance. Marrow cells from C.B-17 scid/scid donors, which cannot generate alloreactive T or B cells, nevertheless are rejected by irradiated allogeneic or F1 hybrid recipient mice. (5) Characterize Hh molecules. 2-D gels of lysates of 35S-methionine labeled EL-4 and various ACCb cell lines, followed by computer analysis of radiographs, identified a 90 kd molecule as a potential candidate for the Hhb antigen. We will generate antibodies to isolate the molecules, and study its structure.
长期的目标是确定基因表达的机制 白血病细胞表面的造血组织相容性(HH)抗原 并对HH分子本身进行鉴定。至 为此,描述了以下目标:1.确认结论 HH抗原在淋巴瘤细胞上的表达被下调 反式调节基因。使用体内和体外检测方法 杂交抗性,其中“冷靶细胞竞争”可以被测量, 我们观察到失去DD的ACCB H-2d/H-2b缺失突变体获得了 HHB的表达。2.更加精确地定位HH基因。B10.RQDB是一种新的 Chella David描述的H-2重组体,表达DD、DB,但不表达 身份证。因此,D和L之间的重组和DB之间的重组真的是 磅。骨髓细胞失去了HHb,为同种异体宿主保留了HHD 降低了F1杂交寄主的HHD。那里和其他新的重组体 将被用来映射HH,这应该是控制L的序列 D(右)L在D区。(3)检验顺式基因假说,即 邻近基因调控HH的表达。使用相同的新H-2重组来 检测S和L之间可能调节HH表达的基因(S) 调节对亲本HH抗原的“耐受性”的杂合子。(4) 继续检验杂交种的“同种异体抑制”假设 抵抗。来自C.B-17 SCID/SCID捐赠者的骨髓细胞,不能 产生同种异体反应的T或B细胞,但被辐射排斥 同种异体或F1杂交受体小鼠。(5)HH分子的表征。 标记EL-4的35S-蛋氨酸裂解产物与不同ACCB细胞的二维凝胶 线条,然后对射线照片进行计算机分析,确定了90kd 分子作为HHB抗原的潜在候选者。我们将生成 抗体来分离分子,并研究其结构。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michael Bennett其他文献

Michael Bennett的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michael Bennett', 18)}}的其他基金

Non-canonical mechanisms of excitotoxicity
兴奋性毒性的非典型机制
  • 批准号:
    10679904
  • 财政年份:
    2023
  • 资助金额:
    $ 8.79万
  • 项目类别:
BLOCKING NEGATIVE SIGNALS TO NK CELLS TO TREAT LEUKEMIA
阻断 NK 细胞的负信号来治疗白血病
  • 批准号:
    6376235
  • 财政年份:
    2000
  • 资助金额:
    $ 8.79万
  • 项目类别:
PATHOLOGY UTSWMC
病理学 UTSWMC
  • 批准号:
    6340695
  • 财政年份:
    2000
  • 资助金额:
    $ 8.79万
  • 项目类别:
BLOCKING NEGATIVE SIGNALS TO NK CELLS TO TREAT LEUKEMIA
阻断 NK 细胞的负信号来治疗白血病
  • 批准号:
    6633105
  • 财政年份:
    2000
  • 资助金额:
    $ 8.79万
  • 项目类别:
BLOCKING NEGATIVE SIGNALS TO NK CELLS TO TREAT LEUKEMIA
阻断 NK 细胞的负信号来治疗白血病
  • 批准号:
    6131639
  • 财政年份:
    2000
  • 资助金额:
    $ 8.79万
  • 项目类别:
BLOCKING NEGATIVE SIGNALS TO NK CELLS TO TREAT LEUKEMIA
阻断 NK 细胞的负信号来治疗白血病
  • 批准号:
    6512815
  • 财政年份:
    2000
  • 资助金额:
    $ 8.79万
  • 项目类别:
INTERNATIONAL CONFERENCE ON THE CEROID-LIOPFUSCINOSES
蜡质-脂褐质国际会议
  • 批准号:
    2723292
  • 财政年份:
    1998
  • 资助金额:
    $ 8.79万
  • 项目类别:
TOLERANCE TO BONE MARROW TRANSPLANTS
对骨髓移植的耐受性
  • 批准号:
    6100018
  • 财政年份:
    1998
  • 资助金额:
    $ 8.79万
  • 项目类别:
TOLERANCE TO BONE MARROW TRANSPLANTS
对骨髓移植的耐受性
  • 批准号:
    6235437
  • 财政年份:
    1997
  • 资助金额:
    $ 8.79万
  • 项目类别:
BLOCKING NEGATIVE SIGNALS TO NK CELLS TO TREAT LEUKEMIA
阻断 NK 细胞的负信号来治疗白血病
  • 批准号:
    2114084
  • 财政年份:
    1996
  • 资助金额:
    $ 8.79万
  • 项目类别:

相似海外基金

Autoimmune disorder in hereditary angioedema
遗传性血管性水肿中的自身免疫性疾病
  • 批准号:
    26460654
  • 财政年份:
    2014
  • 资助金额:
    $ 8.79万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Mechanisms of lymphocyte transmigration across the blood-brain barrier using an in vitro model that mimics blood flow and simulates inflammatory conditions as observed in the most frequent autoimmune disorder of the central nervous system, multiple sclero
使用体外模型模拟血流并模拟在中枢神经系统最常见的自身免疫性疾病多发性硬化症中观察到的炎症状况,从而研究淋巴细胞跨血脑屏障的迁移机制
  • 批准号:
    235301825
  • 财政年份:
    2013
  • 资助金额:
    $ 8.79万
  • 项目类别:
    Research Fellowships
The challenge for the development of therapy for autoimmune disorder by the establishment of artificial thymic medullary organ
人工胸腺髓质器官的建立对自身免疫性疾病治疗发展的挑战
  • 批准号:
    23659241
  • 财政年份:
    2011
  • 资助金额:
    $ 8.79万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了